Please go to the PowerPak homepage
and select a course.
New Evidence to Improve Management of Patients with or at High Risk of ASCVD Events
Jointly provided by Postgraduate Institute for Medicine (www.pimed.com) and Medtelligence.
This activity is supported by an independent educational grant from Amarin Pharma Inc.
June 10, 2019
June 10, 2020
Estimated time to complete the activity:
This innovative CPE activity features leading international experts addressing the reduction of residual risk in patients with, or at high risk of, atherosclerotic cardiovascular disease (ASCVD) beyond LDL-C lowering. The program is based on a live satellite symposium and will include the following topics:
- Omega-3 FAs and their use in patients with ASCVD
- Case simulations on personalization of care in ASCVD
- Pharmacist implications of new cholesterol guidelines and CVOT outcomes trials such as REDUCE-IT
This activity is intended for pharmacists and other healthcare professionals engaged in the management of patients with or at high risk of atherosclerotic cardiovascular disease.
After completing this activity, the participant should be better able to:
- Recognize the difference between omega-3 fatty acids and their formulations to impact ASCVD events, including the negative role of dietary supplements
- Apply evidence-based guidelines and recent randomized clinical trial evidence to lifestyle and therapeutic approaches for managing patients at high risk of cardiovascular events
- Describe the spectrum of major recent ASCVD randomized cardiovascular outcomes trials
Michael B. Bottorff, PharmD, Chair
Professor and Chair
Department of Pharmacy Practice
Manchester College of Pharmacy
Fort Wayne, IN
Daniel E. Hilleman, PharmD
Professor of Pharmacy Practice
Director, Continuing Education
School of Pharmacy and Health Professions
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Medtelligence. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Continuing Pharmacy Education
Postgraduate Institute for Medicine designates this enduring activity for 0.75 contact hour(s) (0.075 CEUs) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number - JA4008162-9999-19-849-H01-P)
Type of Activity: Application
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
- Michael Bottorff, PharmD: Consulting Fees: Esperion; Fees for Non-CME/CE Services: Pfizer
- Daniel Hilleman, PharmD: Fees for Non-CME/CE Services: Amgen
Planners and Managers
The PIM planners and managers have nothing to disclose. The Medtelligence planners and managers have nothing to disclose.
Method of Participation and Request for Credit
There are no fees for participating and receiving CPE credit for this activity. During the period June 10, 2019 through June 10, 2020, participants must read the learning objectives and faculty disclosures and study the educational activity.
If you wish to receive acknowledgment for completing this activity, complete the post-test and evaluation. Participants who successfully complete the activity, post-test, and evaluation will have a statement of credit made available immediately.
If you have any questions regarding the CME certification of this activity, please contact Postgraduate Institute for Medicine at: email@example.com or (303) 799-1930.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
Required Computer Hardware/Software
Please ensure the computer system you plan to use meets the following minimum requirements:
- Operating System: Windows 98 or higher & Macintosh 2.2 or higher
- Internet Browser (Mac &/ Windows): Internet Explorer 6.0 or higher, Google Chrome, Safari 5.0.6 or higher, Firefox 3.0.3 or higher & Opera 5 or higher
- Broadband Internet connection: Cable, High-speed DSL & any other medium that is internet accessible
- Peripherals: Computer speakers or headphones
- Monitor Screen Resolution: 320 x 480 or higher
- Media Viewing Requirements: Adobe Reader, Microsoft PowerPoint, Flash Player & HTML5
For more information, contact Medtelligence at firstname.lastname@example.org.